Status:
UNKNOWN
Prospective, Multicenter HCCIS Evaluation Study
Lead Sponsor:
University of Regensburg
Collaborating Sponsors:
Else Kröner Fresenius Foundation
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
With this prospective, multicenter trial the investigators aim to establish the Hepatocellular Immune Score (HCCIS), a score that has been developed in a retrospective study, as a new tool for risk st...
Eligibility Criteria
Inclusion
- Patients \>18 years old who are receiving primary liver resection in curative intent for HCC after informed consent is obtained.
Exclusion
- Patients who have not given informed consent or who have withdrawn their consent will be excluded from this analysis. In case there is not enough liver tissue for a histological analysis or the remaining liver tissue is not enough to perform a routine pathological analysis patients have to be excluded from the further analysis. In case of an R1 or R2 resection, patients have to be excluded from further analysis. However, these patients will remain in the study as an intention to treat analysis.
Key Trial Info
Start Date :
June 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT02718235
Start Date
June 1 2016
End Date
June 1 2021
Last Update
March 24 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.